Casting light on the national mission to eliminate sickle cell disease in India.
作者信息
Piel Frédéric B, Colah Roshan, Jain Dipty L
机构信息
Department of Epidemiology & Biostatistics School of Public Health, Imperial College London London UK.
National Institute of Immunohaematology Indian Council of Medical Research Mumbai India.
出版信息
Hemasphere. 2024 Oct 19;8(10):e70033. doi: 10.1002/hem3.70033. eCollection 2024 Oct.
Abstract
摘要
相似文献
1
Casting light on the national mission to eliminate sickle cell disease in India.揭示印度消除镰状细胞病的国家使命。
Hemasphere. 2024 Oct 19;8(10):e70033. doi: 10.1002/hem3.70033. eCollection 2024 Oct.
2
Sickle cell anaemia control mission: Implementation of a comprehensive care model in Anuppur, Madhya Pradesh.镰状细胞贫血控制任务：在中央邦安纳普尔实施综合护理模式。
Indian J Med Res. 2024;159(3 & 4):339-346. doi: 10.25259/IJMR_3300_21.
3
Sickle cell disease in tribal populations in India.印度部落人群中的镰状细胞病。
Indian J Med Res. 2015 May;141(5):509-15. doi: 10.4103/0971-5916.159492.
4
Sickle Cell Disease in Central India: A Potentially Severe Syndrome.印度中部的镰状细胞病：一种潜在的严重综合征。
Indian J Pediatr. 2016 Oct;83(10):1071-6. doi: 10.1007/s12098-016-2081-7. Epub 2016 Apr 7.
5
Haemoglobinopathies in India: estimates of blood requirements and treatment costs for the decade 2017-2026.印度的血红蛋白病：2017 - 2026年十年间血液需求量及治疗费用估算
J Community Genet. 2020 Jan;11(1):39-45. doi: 10.1007/s12687-019-00410-1. Epub 2019 Feb 12.
6
Sickle cell disease among tribes of Andhra Pradesh and Orissa, India.印度安得拉邦和奥里萨邦部落中的镰状细胞病。
Anthropol Anz. 2002 Jun;60(2):169-74.
7
Prevalence of the β(S) gene among scheduled castes, scheduled tribes and other backward class groups in Central India.印度中部在册种姓、在册部落及其他落后阶层群体中β(S)基因的流行情况。
Hemoglobin. 2014;38(4):230-5. doi: 10.3109/03630269.2014.931287.
8
Feasibility of a newborn screening and follow-up programme for sickle cell disease among South Gujarat (India) tribal populations.印度古吉拉特邦南部部落人群镰状细胞病新生儿筛查及随访项目的可行性
J Med Screen. 2015 Mar;22(1):1-7. doi: 10.1177/0969141314557372. Epub 2014 Oct 23.
9
Newborn screening shows a high incidence of sickle cell anemia in Central India.新生儿筛查显示印度中部镰状细胞贫血的发病率很高。
Hemoglobin. 2012;36(4):316-22. doi: 10.3109/03630269.2012.691434. Epub 2012 Jun 19.
10
Sickle cell anemia/sickle cell disease and pregnancy outcomes among ethnic tribes in India: an integrative mini-review.印度各民族部落中的镰状细胞贫血/镰状细胞病与妊娠结局：一项综合性小型综述
J Matern Fetal Neonatal Med. 2022 Dec;35(25):4897-4904. doi: 10.1080/14767058.2021.1872536. Epub 2021 Feb 9.
本文引用的文献
1
Advances in pharmacotherapy for sickle cell disease: what is the current state of play?镰状细胞病药物治疗的进展：目前情况如何？
Expert Opin Pharmacother. 2024 Jul;25(10):1325-1334. doi: 10.1080/14656566.2024.2377711. Epub 2024 Jul 8.
2
Sickle cell disease in India: current status and progress.印度的镰状细胞病：现状与进展
Lancet Haematol. 2024 May;11(5):e322-e323. doi: 10.1016/S2352-3026(24)00109-1.
3
Point-of-Care Diagnostic Test for Beta-Thalassemia.即时检测β-地中海贫血症
Biosensors (Basel). 2024 Feb 2;14(2):83. doi: 10.3390/bios14020083.
4
Development of WHO Recommendations for the Final Phase of Elimination and Prevention of Re-Establishment of Malaria.世卫组织关于消除和预防疟疾重新出现的最后阶段的建议的制定。
Am J Trop Med Hyg. 2023 Dec 20;110(4_Suppl):3-10. doi: 10.4269/ajtmh.22-0768. Print 2024 Apr 2.
5
Potential for a large-scale newborn screening strategy for sickle cell disease in Mali: A comparative diagnostic performance study of two rapid diagnostic tests (SickleScan® and HemotypeSC®) on cord blood.马里镰状细胞病大规模新生儿筛查策略的潜力：两种快速诊断测试（SickleScan®和HemotypeSC®）对脐带血的比较诊断性能研究。
Br J Haematol. 2024 Jan;204(1):337-345. doi: 10.1111/bjh.19108. Epub 2023 Sep 20.
6
Genetic counseling in sickle cell disease: Insights from the Indian tribal population.镰状细胞病的遗传咨询：来自印度部落人群的见解。
J Community Genet. 2023 Aug;14(4):345-353. doi: 10.1007/s12687-023-00661-z. Epub 2023 Aug 4.
7
Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission.制定改善镰状细胞病结局的全球战略：柳叶刀血液学委员会。
Lancet Haematol. 2023 Aug;10(8):e633-e686. doi: 10.1016/S2352-3026(23)00096-0. Epub 2023 Jul 11.
8
Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021.全球、区域和国家镰状细胞病的患病率和死亡负担，2000-2021 年：2021 年全球疾病负担研究的系统分析。
Lancet Haematol. 2023 Aug;10(8):e585-e599. doi: 10.1016/S2352-3026(23)00118-7. Epub 2023 Jun 15.
9
Significant haemoglobinopathies: A guideline for screening and diagnosis: A British Society for Haematology Guideline: A British Society for Haematology Guideline.显著血红蛋白病：筛查和诊断指南：英国血液学学会指南：英国血液学学会指南。
Br J Haematol. 2023 Jun;201(6):1047-1065. doi: 10.1111/bjh.18794. Epub 2023 Apr 19.
10
Estimated mortality rates of individuals with sickle cell disease in Brazil: real-world evidence.巴西镰状细胞病患者的估计死亡率：真实世界证据。
Blood Adv. 2023 Aug 8;7(15):3783-3792. doi: 10.1182/bloodadvances.2022008938.
Zotero 插件